Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SclerFIX for Orbital Implant Reinforcement
NCT05236049Phase 1Completed
- Sponsor
- TBF Génie Tissulaire
- Start
- Jul 2019
- Primary completion
- Apr 2022
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SclerFIX in eye cancer, sponsored by TBF Génie Tissulaire. Primary endpoint: Number of complications and adverse events related to SclerFIX set-up at 6 months. Started Jul 2019; status: completed.
02
Drugs
SclerFIX
03
Conditions
eye cancer
Beyond the preview
Go deeper on NCT05236049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05236049.